Elekta AB has signed a memorandum of understanding (MOU) with Belgian company Ion Beam Applications SA (IBA) to collaborate on the development of software and market their products.

The agreement will enable the companies to advance the development of proton therapy treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based in Sweden, Elekta provides clinical solutions for the treatment of cancer and brain disorders.

US-based company Pulse Biosciences Inc plans to raise $30.04m through the private placement of two million shares of its common stock priced at $15.02 each.

The company plans to use the funds towards working capital and general corporate purposes.

“The agreement will enable the companies to advance the development of proton therapy treatments.”

Caresyntax Inc has secured $11.9m in a venture financing round led by Norgine Ventures Management Limited.

The US-based surgical analytics and integration services company plans to use the funds towards product development and to open a new headquarters in Boston.

Chinese medical devices developer Lepu Medical Technology (Beijing) Co Ltd plans to raise CNY3bn ($454.68m) by issuing exchangeable bonds in a private placement.

Discgenics Inc has secured $14m in a series B financing round led by existing investors and Mitsubishi UFJ Capital Co Ltd.

The US-based regenerative medicine company plans to use the funds for the development of its Injectable Discosphere Cell Therapy (IDCT) product in the US and Japan.